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Abstract 
Murine models are widely used valuable tools to study deep vein thrombosis (VT). Leading experts in VT 
research came together through the American Venous Forum to develop a consensus on maximizing the 
utility and application of available mouse models of VT. In this work, we provide an algorithm for model 
selection, with discussion of the advantages, disadvantages, and applications of the main mouse models of 
VT. Additionally, we provide a detailed surgical description of the models with guidelines to validate 
surgical technique.  
Abbreviations 
EIM: Electrolytic Inferior Vena Cava Model; IVC: Inferior Vena Cava; VT: Venous Thrombosis; VTE: 
Venous Thromboembolism. 
Abstract word count:82 





Venous thromboembolism, consisting of deep vein thrombosis (VT) and pulmonary embolism, is 
increasingly seen as a major preventable or treatable disease.  In 2008, the United States Surgeon General 
sent out a “Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism”, which led to 
increased NIH funding and stronger efforts to find therapies for both prevention and treatment of VTE 1
A major preclinical approach for understanding the biology of VT and testing new therapeutics is the use 
of murine models. Many of these models have shown utility in discriminating a number of factors that 
can influence thrombosis—from genetic effects to therapeutic interventions—leading to a better 
. 
Despite moderate success with some of the newer therapies, there is still much room for improvement in 
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mechanistic understanding of VT development and resolution. However, modelselection for addressing 
specific questions is till a poorly defined area, with investigators all too frequently applying one model 
where another might have been more appropriate.  Furthermore, there is a lack of detailed descriptions for 
many applications of presumed “standardized” models, making comparisons among published results 
using the assumed “same” models problematic at best and potentially misleading in the interpretation of 
the findings. Indeed, lack of animal model standardization is a widespread problem beyond the field of 
VT, and careful model selection and characterization should be performed for all disease models.  
The following overview is designed as a guide for how to perform, select, apply, and report seven of the 
major VT models that have been developed in mice. Th se VT models were chosen based on their use 
and thorough characterization to enable reproducibility between laboratories. Beyond the models 
discussed in this work, other models have been reported in publications that are less widely used. This 
work was compiled by experts following detailed discussion of the merits, limitations, and applic tions of 
commonly used murine models of VT during the American Venous Forum Meetings in 2014 and 2015, 
and continued discussions during the writing process of this manuscript. Consideration is given to the 
details of the techniques, reporting of outcome measures, and how a given model and the experimental 
measures derived from its application might best be interpreted in terms of our understanding of clinical 
VT development and resolution.  
2. Mouse Models of Venous Thrombosis 
The murine system has several relatively large and accessible veins.  The most popularly used vein for 
hosting thrombosis is the infrarenal inferior vena cava (IVC) distal to its junction with the left renal vein. 
This region should not be confused with the more proximal region of the vena cava which lies just below 
the heart and is only accessible via thoracotomy. The IVC yields sample sizes sufficient for the study of 
both vein wall tissue and thrombus. The absence of valves in the IVC is a drawback of IVC models when 
comparing to venous thrombi in humans. The other easily accessible large veins are the jugular, the 
femoral and the saphenous veins. The jugular vein is less commonly used for thrombosis models in mice 
because of its highly branching anatomy, variable diameter with dissection or manipulation, and because 
it is rarely the site of VT in humans.  Both the femoral and saphenous veins are directly accessible with a 
simple skin incision and can be used without any dissection, leaving the vein essentially in its natural bed. 
Other venous systems that have been used in thrombosis research are the venules of thin-ti sue structures, 
such as the cremaster muscle, the mesenteric microvasculature, and the ear. Although much has been 
gained from these venule models, they are qualitatively different, and are not categorically large veins. 
The relevance of venule-based models to large-vein thrombosis needs further clarification, and thus these 
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Thrombosis is induced by altering/stopping blood flow, or by free radical endothelial cell activation. 
Thrombus size is commonly used as a metric for understanding the phase of thrombogenesis, thrombus 
amplification, recanalization, and eventual thrombus resolution. It is important to note that these models 
have almost 100% survival, and to our knowledge none of the models cause pulmonary embolism. A 
summary of the well-characterized models is presented in Table 1, with suggested guidelines for 
validation of surgical technique. A detailed description of the surgical procedure for each model is 
provided in the supplemental material. 
2.1. Ligature Based IVC Models 
Ligature models, which include stasis and stenosis models, involve the placement of a ligating or 
stenosing ligature around the IVC just caudal to the left renal vein to achieve stasis or low flw induction 
of thrombosis, respectively.  The selection of this site and the various manipulations are based on the 
capacity to generate a sizable thrombus that can be weighed with a standard micro-balance and 
subsequently evaluated with Western blotting or ELISA, or processed for histlogy or immune-based 
detection of specific antigens. Surgery can be performed in 20-30 minutes, with limited surgical setup 
(anesthesia machine and surgical microscope). In ligature-bas d models, the thrombus forms in the 
upstream distal direction, whereas clinical VTs are generally seen to form downstream from a nidus, such 
as a valve pocket. This reverse direction of growth may not be trivial and requires more investigation. 
However, resulting thrombi have been shown to be structurally similar to human thrombi 2–5
The 
. 
stasis model, also known as the ligation model, seeks to achieve complete stasis in the IVC, 
mimicking the clinical scenario of an occlusive thrombus. Any lateral or lumbar branches draining into 
the IVC between the left renal vein and the iliac bifurcation are interrupted, and the IVC is completely 
ligated. This total stasis leads to a severe vein wall reaction and nearly a 100% incidence of thrombosis. 
This widely used and well-characterized model produces thrombi highly consistent in size, with 10% 
variability 6. A consolidated thrombus (with consistency transitioning between liquid and solid) is 
observed beginning 2 hours post ligation, with reported outcomes extending to 28 days in most mouse 
strains. It has proven valuable in the study of interactions between the vein wall and thrombus during the 
progression from acute (first 2-3 days) to chronic inflammation and remodeling of the vein wall 7,8. 
Retraction of fibrosed thrombus into the vessel wall is observed as a consequence of a total vein 
wall/thrombus retraction at chronic time points, specifically 21 days post thrombosis or further. Avoiding 
interruption of side and/or back branches, even due to surgical challenge, significantly reduces thrombus 
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The St. Thomas stenosis model, named for its development and standardization at St. Thomas Hospital in 
London, involves a combination of reduced blood flow and endothelial damage (two out f three 
components of Virchow’s triad) 10
The St. Thomas stenosis model has been subjected to several surgical modifications that are all broadly 
recognized under the 
. Posterior branches are left intact, while lateral branches are ligated, if 
present. The ligature, placed immediately distal to the left renal vein, is tied over a spacer such as a small 
length of 5-0 Prolene, which is subsequently removed to generate a ~95% reduction in blood flow. A 
neurovascular clamp is then applied to the vena cava wall at two locations in the upstream area for 15-20 
seconds on each location sequentially, which causes apparent “bruising” and an d itional thrombogenic 
stimulus to the vein. This model results in formation of a thrombus under low flow conditions with 90% 
incidence in the Balb/c mouse strain, with moderately lower rates of 75-80% incidence for the C57BL/6 
strain (unpublished observational data).  
stenosis model. Modifications avoid the endothelial damage step, and further vary in 
their treatment of side branches as well as the chosen spacer. One variation leaves all branches open and 
uses a 0.36 mm wire spacer 4, while other variations interrupt side branches and use either a 30-g uge 
needle spacer 3,11–14, or a 0.26 mm wire spacer 15. Experts in the field have noted that these modifications 
which avoid the endothelial damage step open a different and often variable thrombotic process in the 
model. The incidence and size of the resulting thrombus is largely dependent on the variation used; 
ligating side branches draining into the IVC between the left renal vein and iliac bifurcation can increase 
incidence of thrombus induction, and the spacer used has a direct effect on the degree of stenosis. 
Stenosis models result in thrombi that are smaller than those induced with the stasis model. Th  
variability of this model mirrors the variability seen in humans and this may be useful in translating 
findings to the clinic. Variations on the stenosis model may be useful for studying pro-thrombotic 
conditions 16. This model has been used to study early thrombotic events based on the apparent simulation 
of the clinical low-flow risk state 4
Up to today, models performed with stenosis in the IVC have been collectively known as “stenosis 
models” despite the large degree of variation in surgical technique. Due to the amount of variation 
combinations, it is difficult to provide independent names for each surgical technique. Therefore, when 
using a stenosis model, the authors highly suggest listing either “St. Thomas Stenosis Model” or “Stnosis 
Model” with a detailed description of the surgical technique in the methods section of the publication. 
This will clarify to the field the actual surgical approach and serve as a comparative tool between 
laboratories. We also encourage reviewers to ensure thorough descriptions of the specific surgical 
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subjected to the same surgical procedure, as is common in the variations of the stenosis model, are 
welcomed if the research question involves variability in thrombus size, but sho ld be reported.  
2.2. Free Radical Thrombosis Models 
Murine models of free radical induced thrombosis are achieved by either application of ferric chloride to 
the surface of the vein, or an electrolytic application of free radicals using non-injurious direct current to 
deposit metal cations (ferric ions) onto or within the vein. Importantly, free radical models induce 
thrombus formation in the direction of blood flow, as is observed in humans. Additionally, the surgical 
procedures are not as technically difficult compared to ligature-bas d models as no dissection is required 
between the IVC and aorta. 
Free radical induced thrombosis may be performed chemically, using the ferric chloride (FeCl3) model. 
This model has been widely used in murine carotid artery models, and has been adapted for the IVC. A 
small piece of filter paper soaked in a solution of 3.5% ferric chloride by weight in water is applied to the 
IVC for 3 minutes 17. This model may only be used to study very early time points (<1 hour), as the 
mouse cannot be safely recovered with the presence of FeCl3 in the abdominal cavity. If used in the 
jugular or sapheno-femoral vein, however, chronic time points may be studied if the site of applic tion is 
thoroughly irrigated 18. The FeCl3
The 
 applied to the IVC induces a thrombus that is typically very small, 
requiring an ultrasensitive micro-balance (error of measurement should be < 0.05 mg on the balance, as 
the thrombi are typically 1-2 mg) and offering little thrombus material for evaluation. 
femoral vein electrolytic model was designed to combine a simple method of thrombus induction 
commonly used in arterial models with intravital fluorescence microscopy. A 1.5-volt direct current is 
delivered to the surface of the exposed but un-dissected femoral vein for 30 seconds. Modifications in 
time—as short as 1-2 seconds and as long as 90 seconds—as well as current—up to 3 volts—can be used 
if a smaller or larger thrombus is desired, respectively. Thrombus can be studied in both acute and chronic 
time points, with resolution extending out to 28 days in larger thrombi 19. The size of the thrombus is 
generally too small for weight measurements or subsequent protein analysis. The advantage is that the 
relatively small diameter (~0.6 mm) allows application of intravital fluorescence microscopy imaging for 
quantitative analysis of the development of a variety of thrombotic elements at the site of thrombus 
induction 20
The 
. Additionally, the murine femoral vein has valves, which are thought to play an important 
role in human thrombogenesis. 
electrolytic IVC model (EIM) induces thrombosis by constant current application to a copper wire 
inserted into the IVC 21–23. This generates free radicals in the wire which activate endothelial cells without 
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remain open. Thrombi develop quickly, forming in the direction of maintained blood flow (without 
causing occlusion), with consistent size which can be evaluated for weight and subsequent protein/cellular 
composition 23. Electrolysis does not alter intravascular temperature, but does require a longer operative 
time for current application and some damage to the vein wall at the needle insertion ite. It is important 
to note that the needle insertion causes a 0.5 mm tear in the endothelial layer, which represents 14% of the 
vessel perimeter 24; insertion of the needle without current application does not induce thrombosis 23. The 
EIM is recommended for the study of anti-thrombotic, thrombolytic agents or any new agents in VT 
treatment and prophylaxis. Recently the EIM application was expanded for the study of pro-thrombotic 
conditions 25,26. Further, imaging studies recently demonstrated the consistent thrombus size is both 
current and time dependent, enabling researchers to modify these parameters to create thrombi of 
consistent size to study both pro-thrombotic and anti-thrombotic phenotypes, supporting the modification 
introduced in 2015 27. Additionally, a new approach was recently introduced to address lack of equipment 
availability and high cost, following the same principles but significantly reducing equipment cost 27
2.3. Model of Recurrent Venous Thrombosis 
.  
Among VT patients, 30% will suffer a recurrent episode within ten years, with 45% occurring in the 
ipsilateral leg leading to an increased risk of post thrombotic syndrome. The IVC r current VT model was 
thus developed to investigate this biology by producing two episodes of VT in the same animal. Because 
of the high rate of recurrent thrombosis in humans, this model is a novel and direct application to the 
human condition. The initial thrombus is induced using the electrolytic IVC model (EIM), and a 
secondary episode is induced 21 days later using either the EIM or a ligature-b sed model. At the time of 
induction of the secondary episode, the primary thrombus has become incorporated into he vein wall and 
the lumen has been recovered. Using EIM as the primary insult allows for continuous blood flow and the 
opportunity to induce a second episode without needing to remove any ligature. This clinically relevant 
model has proven valuable in the study of recu rent VT biology 28
3. Comparison and Critique of the Models 
. 
An ideal model would recapitulate the disease onset and pathology that are seen clinically.  Because of 
our relative lack of understanding about VT development and progression, current animal models 
represent our “best guess”, and thus, may lack critical features of clinical VT.  A likely scenario for VT 
development, frequently presented by many in the field, is a low-flow or stasis state within the vein, often 
in a valve pocket, which can be compounded by genetic or acquired systemic prothrombotic propensity, 
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mimic thrombogenesis in its natural form, but we can use them to study the stages of VT once a thrombus 
has formed. 
Each model has its own unique benefits and limitations. For example, ligature-b sed models use slow 
flow or an occlusion to generate the thrombus. This is an opposite scenario to clinical VT development, 
for which the thrombus generates occlusion of the vein, with the exception of May-Thurner syndrome and 
portions of thrombus that develop distally following total occlusion. The free-radical-based models 
induce rapid thrombus growth and are more attuned to testing acute thrombogenesis.  Th  maintained 
flow in the vein, with the possibility of thrombus regression or embolization, provides a level of relevance 
not available with the ligature-based models. It should be noted that while stenosis models are often 
thought of as blood flow models, the resulting thrombus often leads to full stasis as the thrombus occludes 
the site of stenosis.  
While most models may be used to study both pro-th mbotic and anti-thrombotic phenotypes, the 
research question may lead investigators to consider the sensitivity required for detecting differences 
between experimental groups. For example, the IVC stasis (ligation) model creates a close to peak growth 
in control conditions, so it is mostly relevant for evaluating anti-thrombotic phenotypes, i.e. experimental 
conditions expected to reduce thrombus size. In the case of pro-thrombotic phenotypes, a large effect 
should be expected for adequate sensitivity when using the stasis model 5,29. In contrast, the stenosis 
model variations have a lower thrombus incidence and smaller thrombus size under control conditions, so 
these may be applied to pro-thrombotic phenotypic testing, with attention paid to rates of incidence 
between experimental groups. The EIM produces thrombi sufficiently large to test anti-thrombotic 
therapeutics, and may also be adjusted (decreasing the current or duration of current application) to study 
pro-thrombotic conditions 25
It is of the utmost importance that publications give clear and detailed descriptions of the model with 
justification of any modifications used in the materials and methods section. Additionally, for rigorous 
science we recommend reporting data regardless of whether a thrombus developed in all mice, as 
variation in thrombus incidence could have important research implications. Further, robust end-point 
measures should be taken into consideration dependent on the model chosen during experimental design 
. 
30. Researchers should continually strive to balance accurate and rigorous science with the highest 
standards of animal care, with the principles of the 3Rs (refinement, replacement and reduction) firmly in 
mind. The authors are therefore opposed to increasing the number of animals to match a representative or 
significant number, unless this is highly justified towards a specific research question. An initial power 
calculation should be carried out based on the variability of the endpoint measure chosen in order to 















This article is protected by copyright. All rights reserved 
4. Choosing A Model for Your Research Question 
There is no single “best” model to represent this complex disease in all its stages. Therefore, the choice of 
model should be based on the specific research question. Investigators should consider the clinical 
scenario the model should represent, including relevant time points, what outcomes will be measured, the 
strain of mouse that will be used, and available resources. All surgical models require a su gic l 
microscope and anesthesia. Given the faster metabolic rate of mice compared to humans, thrombi ≤  3 
days old are considered acute, and the thrombi naturally resolve and become incorporated into the vein 
wall by day 28. When studying chronic VT, it can become increasingly difficult to remove the thrombus 
from the vein wall from 14 days following induction, which can hamper analysis. 
Once a research question has been clearly defined, Fig. 1 may provide an aid in model selection. Because 
a clear “best murine model” for simulating VT does not exist, a practical and more generalizable 
approach to experimental investigations of VT is to apply two or more diffrent models under similar 
conditions, such as in evaluating new transgenic/knockout mouse lines or ovel pharmaceutical therapies 
14
In choosing a mouse strain, it is important to note the anatomical differences between mice from BALBc 
vs. C57BL/6 backgrounds. BALB/c mice have very few if any lateral branches compared with C57BL/6. 
Although posterior branches in BALB/c mice are increased in number, they are of a smaller caliber than 
in C57BL/6 mice. Thrombus size is generally larger and less variable in BALBc compared to C57BL/6 
mice (Table 1). There are, however, far more genetically-modified mice available on a C57BL/6 
background. 
.  By using multiple mechanisms for inducing thrombus growth in a vein, a broader representation of 
thrombogenesis is presented for testing a potential phenotype. Relevant options for secondary models are 
listed under each model in Fig. 1. The selected models should have a response range that is commensurate 
with the anticipated or hypothesized response.   
An important note for any model requiring the interruption of lateral br nches is that in female mice from 
the C57BL/6 background, the right uterine vein commonly drains into the IVC, with ligation resulting in 
necrosis of the reproductive organs 32
In conclusion, there is no single “best” model to study VT, as areas of peri-thrombus blood flow and total 
stasis occur in human deep vein thrombosis. Model selection should be determined by the specific 
. Thus, if an IVC model is being used, either the stenosis model 
variation that does not interrupt branching vessels or the use of BALB/c mice (which typically do not 
present lateral branches) is recommended to study VT in females. If mice from the C57BL/6 background 
are used, the branching phenotype should be noted as a variable influencing thrombus size and larger 
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research question, and an additional model should be implemented to examine the experimental 
conditions under more than one setting. While no single mouse model can capture the complexity of VT, 
this method brings us closer to a rigorous understanding of the disease. 
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• This consensus details step-by-step surgical procedures in the supplemental material, providing a 
one-stop shop for investigators to understand how to surgically perform the models.  
Highlights 
• Specific guidelines on thrombus size are provided to enable researchers performing these 
techniques to validate their surgical technique against this standard.  
• The advantages and disadvantages of each model are discussed in detail with consideration to 
potential application of each model.  
• An algorithm for model selection is provided which guides researchers in selecting a model to 
match the specific research question, and further suggests useful secondary models to explore 
the research question in more than one setting.  
 
Figure 1. Model selection algorithm. This flow chart may serve as a starting point for considerations in 
model selection. No single model is adequate to capture the complexity of VT; thus we recommend 
alternatives and secondary model options below each model. Mouse strain and sex should also be 
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branches draining into the IVC (common in mice from a C57 background) may not be interrupted in 
female mice. 
Table 1.  A listing of the well-characterized murine DVT models, guidelines for surgical validation, and 
their advantages and disadvantages. Guidelines for surgical validation are provided for models with 
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Table 1.  A listing of the well-characterized murine DVT models, guidelines for surgical validation, and 
their advantages and disadvantages. Guidelines for surgical validation are provided for models with 
predictable outcomes in thrombus size, intended for training purposes on data reproducibility.  
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are ligated and 
posterior branches 
are cauterized. 
The IVC is 
ligated with a 
nonreactive suture 
ligature placed 
just distal to the 
left renal vein 
95-100% Large (<10% variation); 
In 9 to 10-week-old 
male C57BL/6 mice 
weighing 25 grams, 
thrombus weights (IVC 
+ thrombus at harvest) 
should be approximately 
33 mg at day 2, 29 mg at 
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Moderate to large (20% 
variation); In a 25g male 
BALB/C mouse, 
thrombus weight should 
be approximately 20 mg 
at 24 hours with a 
volume of 18 mm3. 
C57BL/6 mice produce 
slightly smaller thrombi 
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variation) 
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Small (≤250 A) 
direct current 
applied to copper 
wire with the end 
inserted into a 25-
gauge needle. 
Needle is placed 
inside the IVC on 
the anterior wall 
for ≤15 min. 
Lateral branches 
are ligated. 
100% Current and time 
dependent – moderate to 
large (<10% variation); 
10-week-old 25 g 
C57BL/6 mice show 
approximate thrombus 
weights (IVC+thrombus 
at harvest) of 17 mg at 2 
days, 12 mg at 6 days, 
and 8 mg at 14 days 
when induced with 250 
µA for 15 min. 
Thrombus forms 





ability to modify 
current or 
application time 









A piece of filter 
paper satured in a 
solution of FeCl3 
is placed on the 
IVC 
100% Concentration and time 
dependent—Small (20% 
variation); In 20-25g 
male C57BL6 mice, the 
wet thrombus weight 
(separated from the IVC 
in saline) should be 
Thrombus forms 
in direction of 
blood flow; 
ability to modify 
concentration or 
application time 
to fit research 
Only early time 
points (≤1 hour) 
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approximately 1.3 mg at 
30 minutes following 
induction with 3.5% 
FeCl3 applied for 3 
minutes. 






A 1.5 to 3-volt 
direct current is 




application of 30 
seconds; 
modifications can 
range from 1s up 
to 2 min) 
100% Current and time 
dependent—Small (25% 
variation); In 12-16 
week old male C57BL6 
mice, thrombus 
histomorphometric 
volume should be 0.015 
mm3 at day 1 when 
induced with 1.5V for 
30 seconds, or 0.140 
mm3 at day 1 when 








in direction of 
blood flow; 
ability to modify 
current or 
application time 










Recurrent VT  EIM is 
performed, and 21 




either EIM or a 
ligature-based 
IVC model 
100% Moderate to large (20% 
variation) – the EIM and 
surgical procedure for 
the secondary method to 
be used should be 
validated using the 
guidelines above 












into the vein 
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